Form 4: NeuroOne Medical Technologies CEO Acquires Options to Purchase 750,000 Shares
SEC Form 4 Filing
NeuroOne Medical Technologies CEO, David A. Rosa, acquired options to purchase 750,000 shares of common stock on April 17, 2025, at an exercise price of $0.5796.
Summary
- On April 17, 2025, David A. Rosa, CEO and President of NeuroOne Medical Technologies Corp, acquired options to purchase 750,000 shares of the company's common stock.
- The exercise price for these options is $0.5796 per share.
- These options vest over time, with 25% vesting on April 17, 2026, and the remaining 75% vesting in 12 equal quarterly installments.
- Following the transaction, Mr. Rosa directly owns options to purchase 750,000 shares.
- The options expire on April 16, 2035.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company executives.
Stakeholder Impact
- Shareholders may be interested in the CEO's holdings and transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 04/17/2025 | Date of transaction: CEO acquired options to purchase common stock. |
| 04/17/2026 | 25% of the options vest. |
| 04/16/2035 | Expiration date of the options. |
| 04/21/2025 | Date of Form 4 filing. |
Keywords
NeuroOne Medical Technologies, NMTC, David A. Rosa, Stock Options, Form 4, Insider Trading, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.